Herbert Smith Freehills Kramer is a world-leading global law firm, where our ambition is to help you achieve your goals. Exceptional client service and the pursuit of excellence are at our core. We invest in and care about our client relationships, which is why so many are longstanding. We enjoy breaking new ground, as we have for over 170 years. As a fully integrated transatlantic and transpacific firm, we are where you need us to be. Our footprint is extensive and committed across the world’s largest markets, key financial centres and major growth hubs. At our best tackling complexity and navigating change, we work alongside you on demanding litigation, exacting regulatory work and complex public and private market transactions. We are recognised as leading in these areas. We are immersed in the sectors and challenges that impact you. We are recognised as standing apart in energy, infrastructure and resources. And we’re focused on areas of growth that affect every business across the world.
This podcast focuses on the pharmaceutical industry and, in particular, M&A activity in the sector and the recent surge in licensing deals involving Chinese biotechs.
United KingdomFood, Drugs, Healthcare, Life Sciences
Herbert Smith Freehills Kramer LLP’s articles from Herbert Smith Freehills Kramer LLP are most popular:
within Food, Drugs, Healthcare and Life Sciences topic(s)
with readers working within the Insurance, Property and Law Firm industries
Herbert Smith Freehills Kramer LLP are most popular:
within Wealth Management, Employment and HR and Transport topic(s)
with Senior Company Executives, HR and Inhouse Counsel
This podcast focuses on the pharmaceutical industry and, in particular, M&A activity in the sector and the recent surge in licensing deals involving Chinese biotechs. There are a lot of interesting topics related to the pharmaceutical sector which we could discuss but today we will be covering the following: 1) First, we will begin with an overview of M&A deal activity in the sector; 2) we will then discuss the key legal trends being seen by our deal teams, 3) finally, we will conclude with a discussion on a hot topic in the industry right now, the rise of China's biotechs on the global stage.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
